Dr. Shervin Assassi, MD

Dr. Assassi practices at UT Physicians in Houston, Texas.

Dr. Assassi's NPI, 1043259567, was assigned on June 6, 2006. Dr. Assassi graduated from Albert Ludwigs University Faculty of Medicine in 1999. Dr. Assassi's Texas license number on file is M2251.

Dr. Assassi's primary practice is UT Physicians, at 6410 Fannin St, Houston, TX 77030 in Harris County. The practice phone is (832) 325-7325.

Dr. Assassi's primary practice is UT Physicians in Houston, Texas. Dr. Assassi is also affiliated with Memorial Hermann-Texas Medical Center. The medical group on file is UT Physicians. Dmand AI also links Dr. Assassi to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Assassi practices, 3 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Assassi's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Assassi is board certified in rheumatology by the American Board of Internal Medicine. Dr. Assassi has a license on file in Texas.

Dmand AI lists arteritis, arthritis, joint pain, muscle pain, fibromyalgia, and limb pain, osteoporosis and rheumatoid arthritis among the conditions Dr. Assassi treats.

CMS data shows 91 Medicare services from Dr. Assassi across 2 procedure codes in 2024, for 60 Medicare patients. Medicare paid $4,825 for them. Every service was in an office.

CMS counts 60 Medicare patients who saw Dr. Assassi in 2024. The largest group is 65 to 74, with 34 patients. 75% of them have high blood pressure, and 68% have arthritis. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Assassi's median patient age at 61, with 75% women.

In 2024, Dr. Assassi wrote 589 Medicare Part D claims for 74 patients. 88% of them were for generic drugs. CMS names the drug for 443 of them, across 18 drugs with 11 or more claims each, at $266,803 in total drug cost. In 2023, CMS named 449 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Assassi for performance year 2024, reported as part of a group. Dr. Assassi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 245 papers to Dr. Assassi, published from 2003 to 2025. 2019 was the busiest year, with 18. The most frequent topics are Scleroderma, Systemic, Genetic Predisposition to Disease and Autoantibodies. Dr. Assassi has published most often in Ann Rheum Dis. Dr. Assassi's most frequent co-authors are Maureen D. Mayes, MD, John D. Reveille, MD and Dinesh Khanna, MD.

Dmand AI links Dr. Assassi to 1 clinical trial. Conditions studied include Lupus Erythematosus, Systemic and Connective Tissue Diseases. Open Payments lists research payments to Dr. Assassi that name 1 trial.

CMS Open Payments shows 332 general payments to Dr. Assassi from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 58% of the total. Boehringer Ingelheim USA, Inc. paid the most, $196,243. It also lists 2 research payments totaling $6,100 from 2021 to 2024, naming 1 clinical trial.

Dmand AI lists 2 awards for Dr. Assassi.

Dr. Assassi graduated from Albert Ludwigs University Faculty of Medicine in 1999. Dr. Assassi is a member of ACR.

Dr. Assassi is in network with 21 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.